Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate

NCT03240211 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT03240211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03240211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate
Lead sponsor
University of Virginia
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 2, 2022
Completion date
May 25, 2026
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ctcl, ptcl